682
Participants
Start Date
April 15, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2030
Neoadjuvant apatinib combined with sintilimab and perioperative SOX
Sintilimab: 200mg, iv, day 1 Oxaliplatin: 130 mg/m², iv, day 1 S-1: 40-60 mg/m², po, day 1-14 (BSA \< 1.25 m², 40 mg bid, 1.25 m² ≤ BSA \< 1.5 m², 50 mg bid, BSA ≥ 1.5 m², 60 mg bid) Apatinib: 250mg, po, day1-21, for 3 cycles preoperatively
Neoadjuvant sintilimab combined with perioperative SOX
Sintilimab: 200mg, iv, day 1 Oxaliplatin: 130 mg/m², iv, day 1 S-1: 40-60 mg/m², po, day 1-14 (BSA \< 1.25 m², 40 mg bid, 1.25 m² ≤ BSA \< 1.5 m², 50 mg bid, BSA ≥ 1.5 m², 60 mg bid)
RECRUITING
First Hospital of Lanzhou University, Lanzhou
RECRUITING
Gansu Provincial Hospital, Lanzhou
RECRUITING
Lanzhou University Second Hospital, Lanzhou
RECRUITING
The Gastrointestinal Surgery Department, Sun Yat-sen University Cancer Center Gansu Hospital, Lanzhou
Zuoyi Jiao
OTHER